Smith & Wesson Brands (SWBI) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
11 Jan, 2026Executive summary
Q2 net sales rose 3.8% year-over-year to $129.7 million, with GAAP net income of $4.1 million ($0.09 per share) and gross margin improving to 26.6% from 25.4% last year.
New products accounted for 44% of Q2 sales, led by the Bodyguard 380 pistol and lever action rifles.
Adjusted EBITDAS margin was 14.3%, down from 15.5% in the prior year quarter.
Flexible manufacturing and innovation enabled market share gains despite industry headwinds and demand normalization late in the quarter.
For the six months ended October 31, 2024, net sales declined 8.9% to $218.0 million, with net income of $2.0 million ($0.04 per share).
Financial highlights
Q2 net sales were $129.7 million, up 3.8% year-over-year, driven by new product launches.
Gross margin for Q2 was 26.6%; non-GAAP gross margin was 27.1%.
Q2 operating income was $7.0 million (5.4% margin), up 85% year-over-year.
Cash used in operations was $38.2 million for the six months, mainly due to a $35.5 million inventory increase.
$22.6 million in share repurchases and $11.7 million in dividends paid in the six months.
Outlook and guidance
Full-year revenue is expected to be 5%-10% lower than fiscal 2024 due to softer demand and inflationary pressures.
Q3 revenue projected to be 10%-15% lower year-over-year, with margins a few points lower.
Operating expenses for Q3 are expected to be 5%-10% higher than last year due to increased R&D, promotions, and marketing.
Inventory levels expected to decline in the remainder of the fiscal year.
Year-end debt levels are expected to be similar to or slightly above last year, with cash generation below the $75 million target.
Latest events from Smith & Wesson Brands
- Q3 net sales up 17.1% to $135.7M, with higher margins and strong Q4 outlook.SWBI
Q3 20265 Mar 2026 - Double-digit growth in revenue and net income, with 2025 outlook for continued gains and higher dividends.SWBI
Q4 20243 Feb 2026 - Q1 sales fell 22.7%, but new products and margin gains support a positive full-year outlook.SWBI
Q1 202522 Jan 2026 - Board re-elections, executive pay approval, and strong financial growth highlighted the meeting.SWBI
AGM 202420 Jan 2026 - Q3 sales fell 15.7% as new products drove 41% of revenue, but margins and sales remain pressured.SWBI
Q3 202527 Dec 2025 - Q2 sales dipped 3.9% but cash flow and new product momentum support a strong Q3 outlook.SWBI
Q2 20267 Dec 2025 - Director elections, say-on-pay, and a human rights proposal headline a governance-focused agenda.SWBI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor ratification, all board-backed.SWBI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.SWBI
Proxy Filing1 Dec 2025